OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

Genmab A/S GENMAB ORD SHS/  DK0010272202  /

LSE International Off-book
10/4/2024  4:59:49 PM Chg. -7.00 Volume Bid10/4/2024 Ask10/4/2024 Market Capitalization Dividend Y. P/E Ratio
1,587.50DKK -0.44% 2,353
Turnover: 3.71 mill.		 -Bid Size: - -Ask Size: - 104.89 bill.DKK - 23.82
GlobeNewswire 8/19 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire 8/8 Genmab Announces Financial Results for the First Half of 2024
GlobeNewswire 8/8 Genmab Updates 2024 Financial Guidance
GlobeNewswire 8/5 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 8/5 Genmab Takes Full Control of Acasunlimab Development Program
GlobeNewswire 6/28 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire 5/21 Genmab Completes Acquisition of ProfoundBio
GlobeNewswire 5/21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire 5/6 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 5/2 Genmab Announces Financial Results for the First Quarter of 2024
GlobeNewswire 4/30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 4/3 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire 3/20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 2/14 Genmab Announces Initiation of Share Buy-Back Program
GlobeNewswire 2/14 Genmab Publishes 2023 Annual Report
GlobeNewswire 1/9 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 11/9/2023 Major Shareholder Announcement
GlobeNewswire 11/8/2023 Major Shareholder Announcement
GlobeNewswire 11/7/2023 Genmab Announces Financial Results for the First Nine Months of 2023
GlobeNewswire 11/6/2023 BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire 10/17/2023 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire 9/25/2023 Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire 9/4/2023 Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire 2/24/2022 Notice to Convene the Annual General Meeting of Genmab A/S
GlobeNewswire 2/16/2022 Genmab Publishes 2021 Annual Report